Earnings Preview: Gilead Sciences Set to Report Q4 2024 Results
Biopharmaceutical company Gilead Sciences, Inc. (NASDAQ:GILD) is gearing up to release its Q4 2024 earnings on February 11, 2025. Analysts expect the company to post an EPS of $1.55, down from $1.72 in the year-ago period. Quarterly revenue is anticipated to reach $7.14 billion, slightly up from $7.12 billion in the same period last year.
Strong Q3 2024 Earnings
Gilead Sciences reported its Q3 2024 earnings on November 6, posting an adjusted EPS of $2.02, surpassing the consensus estimate of $1.55. The company’s revenue reached $7.54 billion, exceeding the consensus of $7 billion. Chairman and CEO Daniel O’Day attributed the strong results to 7% year-over-year revenue growth, including 13% year-over-year growth for Biktarvy.
Full-Year Guidance Raised
Based on the strong Q3 performance, Gilead Sciences raised its full-year revenue, operating income, and earnings per share guidance. The company now expects full-year product sales to range from $27.8 billion to $28.1 billion, up from the prior guidance of $27.1 billion to $27.5 billion.
Attractive Dividend Yield
Gilead Sciences offers an attractive dividend yield of 3.38%, with a 52-week range of $62.07 to $98.90. Over the past 12 months, the company paid $3.08 per share in dividends. To generate an income of $100 per month, investors would need to own approximately 390 shares of stock, valued at around $35,503.
Understanding Dividend Yield Calculations
Dividend yield calculations involve two key variables: the desired annual income and the dividend yield. By dividing the annual dividend payments by the stock’s current price, investors can calculate the dividend yield. However, the dividend yield can fluctuate over time due to changes in stock prices and dividend payments.
Income-Focused Investors Take Note
Gilead Sciences’ consistent dividend hikes and attractive dividend yield make it an appealing option for income-focused investors. With a history of raising dividends consecutively for nine years, investors may benefit from the company’s steady income stream.
Alternative Investment Opportunities
For investors seeking alternative income streams, platforms like EquityMultiple offer short-term note investments with attractive rates of return. The Alpine Note — Basecamp Series, for instance, offers a 9% rate of return (APY) with a 3-month term and a $5,000 minimum investment.
Leave a Reply